Morgan Stanley assigned several buy-rated global stocks that it expects to outperform. In a note to investors, the firm asked analysts to pick stocks from a list in which they “particularly believe the market is not pricing in current earnings announcements.” The bank picked three pharma stocks with buy ratings (or “overweight”), including Novo Nordisk, maker of weight-loss drug Ozempic. “We expect Ozempic to further raise its guidance ahead of its second-quarter results,” the analysts wrote. The company reported on Aug. 10. Other drugmakers the bank likes include Grifols, which Morgan Stanley says expects “solid results,” and Indivior, which Morgan Stanley says is set for a “strong quarter.” Deutsche Telekom was on the buy list for its improving prospects with “better trends in the US (and) Germany”, while entertainment company Scout24 was favored by the bank for its “steady” subscription revenue. French materials maker Saint-Gobain is also an option for Morgan Stanley, and the bank said the consensus did not yet reflect the optimism on margins discussed by its management at last month’s annual shareholder meeting. Energy company RWE is an overweight pick for analysts who expect upward EPS revisions going forward. “The post-coronavirus earnings season has become an exercise in positive surprises,” analysts led by Giorgio Magnagnotti wrote in a July 14 note. “While the second quarter of 2023 could see another positive beat rate, slowing global and European economic momentum suggests that the above-mentioned beats will be close to normal,” they added.